Posted by Michael Wonder on 24 Oct 2019
Novartis receives approval for Cosentyx label update in Europe to include dosing flexibility in ankylosing spondylitis
24 October 2019 - New Cosentyx (secukinumab) label to include 300 mg up-titration option is informed by results from the Phase III MEASURE 3 study.
Novartis, a leader in rheumatology and immuno-dermatology, announced today that the European Commission has approved a label update for the up-titration of Cosentyx (secukinumab) to 300 mg for patients with active ankylosing spondylitis (AS).
The approval is based on data from MEASURE 3, a three-year study that explored the tolerability and efficacy of Cosentyx in patients with AS. Response rates were greater in the 300 mg dose group, particularly among patients with previous anti-TNF exposure, compared with the recommended 150 mg dose. The safety profile was consistent with previous studies.
